1 |
Kalia LV, Lang AE. Parkinson′s disease[J]. Lancet,2015,386(9996):896-912.
|
2 |
Lubomski M, Xu X, Holmes AJ, et al. The Gut Microbiome in Parkinson′s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies[J]. Front Aging Neurosci, 2022,4:875261.
|
3 |
Lubomski M, Davis RL, Sue CM. Gastrointestinal dysfunction in Parkinson′s disease[J]. J Neurol,2020,267(5):1377-1388.
|
4 |
Simonet C, Bestwick J, Jitlal M, et al. Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population[J]. JAMA Neurol,2022,79(4):359-369.
|
5 |
Tansey MG, Wallings RL, Houser MC, et al. Inflammation and immune dysfunction in Parkinson disease[J]. Nat Rev Immunol,2022,22(11):657-673.
|
6 |
中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业.中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268-271.
|
7 |
袁德智,胡洁,赵秋叶,等.帕金森病进展速度与抑郁、睡眠障碍的相关性分析[J].中国医科大学学报,2020,49(4):326-330.
|
8 |
曲艳,李晓红,孙亚南,等.汉化版MDS-UPDRS与传统UPDRS评测帕金森病的比较分析[J].中国康复理论与实践,2019,25(8):936-939.
|
9 |
申婉晴,史新冲,张冰,等.帕金森病非运动症状与纹状体囊泡单胺转运蛋白2密度的相关性[J].中华核医学与分子影像杂志,2021,41(3):129-135.
|
10 |
赵安容,李波,徐世成,等.低频与高频rTMS对帕金森病患者运动功能和自主神经功能障碍的影响[J/OL].中华临床医师杂志(电子版),2020,14(10):779-784.
|
11 |
Han MN, Finkelstein DI, McQuade RM, et al. Gastrointestinal Dysfunction in Parkinson′s Disease: Current and Potential Therapeutics[J]. J Pers Med, 2022,12(2):144.
|
12 |
Knudsen K, Fedorova TD, Bekker AC, et al. Objective Colonic Dysfunction is Far more Prevalent than Subjective Constipation in Parkinson′s Disease: A Colon Transit and Volume Study[J]. J Parkinsons Dis, 2017,7(2):359-367.
|
13 |
O′Day C, Finkelstein DI, Diwakarla S, et al. A Critical Analysis of Intestinal Enteric Neuron Loss and Constipation in Parkinson′s Disease[J]. J Parkinsons Dis, 2022,12(6):1841-1861.
|
14 |
Rodríguez-Ramallo H, Báez-Gutiérrez N, Prado-Mel E, et al. Association between Anticholinergic Burden and Constipation: A Systematic Review[J]. Healthcare (Basel), 2021,9(5):581.
|
15 |
O′Donovan SM, Crowley EK, Brown JR, et al. Nigral overexpression of α-synuclein in a rat Parkinson′s disease model indicates alterations in the enteric nervous system and the gut microbiome[J]. Neurogastroenterol Motil, 2020,32(1):e13726.
|
16 |
Barbe AG, Heinzler A, Derman S, et al. Hyposalivation and xerostomia among Parkinson′s disease patients and its impact on quality of life[J]. Oral Dis, 2017,23(4):464-470.
|
17 |
Umemoto G, Fujioka S, Iwasa Y, et al. Impact of Progression of Parkinson′s Disease on Swallowing Ability and Oral Environment[J]. Parkinsons Dis, 2021,2021:5571556.
|
18 |
Bhidayasiri R, Phuenpathom W, Tan AH, et al. Management of dysphagia and gastroparesis in Parkinson′s disease in real-world clinical practice-Balancing pharmacological and non-pharmacological approaches[J]. Front Aging Neurosci, 2022,14:979826.
|
19 |
Sauerbier A, Ray Chaudhuri K. Non-motor symptoms: the core of multi-morbid Parkinson′s disease[J]. Br J Hosp Med (Lond), 2014,75(1):18-24.
|
20 |
杨玉杰,戚志强,陆敏艳,等.同型半胱氨酸与帕金森病的临床相关性研究[J].中华老年心脑血管病杂志,2018,20(3):305-306.
|
21 |
Xiong KP, Dai YP, Chen J, et al. Increased Serum Cystatin C in Early Parkinson′s Disease with Objective Sleep Disturbances[J]. Chin Med J (Engl), 2018,131(8):907-911.
|
22 |
张家和,柯开富,施建生,等.血尿酸、CysC及Hcy与老年帕金森病患者病程及疾病严重程度相关性分析[J].中国医药导报,2022,19(5):82-85.
|
23 |
Yu QJ, Yu SY, Zuo LJ, et al. Parkinson disease with constipation: clinical features and relevant factors[J]. Sci Rep, 2018,8(1):567.
|